4//SEC Filing
Ashe Andrew D. 4
Accession 0001209191-22-047882
CIK 0001840574other
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 5:00 PM ET
Size
14.7 KB
Accession
0001209191-22-047882
Insider Transaction Report
Form 4
Ashe Andrew D.
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2022-08-25$2.87/sh+10,835$31,096→ 266,509 total - Exercise/Conversion
Common Stock
2022-08-25$1.48/sh+33,749$49,949→ 255,674 total - Exercise/Conversion
Common Stock
2022-08-25$1.39/sh+51,203$71,172→ 221,925 total - Exercise/Conversion
Stock Option (right to buy)
2022-08-25−51,203→ 0 totalExercise: $1.39Exp: 2028-11-07→ Common Stock (51,203 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-08-25−10,835→ 153,278 totalExercise: $2.87Exp: 2030-09-15→ Common Stock (10,835 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-08-25−33,749→ 26,999 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (33,749 underlying)
Footnotes (3)
- [F1]The remaining shares underlying this option, which was granted on November 8, 2018, were fully vested as of August 20, 2022.
- [F2]The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until July 26, 2023.
- [F3]The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001573163
Filing Metadata
- Form type
- 4
- Filed
- Aug 28, 8:00 PM ET
- Accepted
- Aug 29, 5:00 PM ET
- Size
- 14.7 KB